DrugPatentWatch Database Preview
Patent: 10,035,843
Summary for Patent: 10,035,843
| Title: | RSV-specific binding molecule |
| Abstract: | The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. |
| Inventor(s): | Beaumont; Tim (Ouderkerk aan de Amstel, NL), Bakker; Adrianus Q. (Hoorn, NL), Yasuda; Etsuko (Amsterdam, NL) |
| Assignee: | MedImmune Limited (Cambridge, GB) |
| Application Number: | 15/042,656 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,035,843
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medimmune | SYNAGIS | palivizumab | VIAL | 103770 | 002 | 1998-06-19 | Start Trial | MedImmune Limited (Cambridge, GB) | 2029-10-06 | RX | search | |
| Medimmune | SYNAGIS | palivizumab | VIAL | 103770 | 001 | 1998-06-19 | Start Trial | MedImmune Limited (Cambridge, GB) | 2029-10-06 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,035,843
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 2012070446 | Start Trial |
| United States of America | 2014093500 | Start Trial |
| United States of America | 2016251412 | Start Trial |
| United States of America | 2019040120 | Start Trial |
| United States of America | 8568726 | Start Trial |
| United States of America | 9283274 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
